Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01605370 · ClinicalTrials.gov registry record · Phase 4
Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?
A Phase 4 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT01605370: Clinical Trial Phase 4 study, sponsored by Mayo Clinic.
NCT01605370 is a Phase 4 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 1 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01605370, a Phase 4 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate if a drug called nebivolol can reverse inappropriate left ventricular mass (LVM) when compared to the standard of care drug metoprolol.
Primary Outcome
LVM will be measured by echocardiography exam. LVM is inappropriate when observed LVM (oLVM) exceeds predicted LVM (pLVM) by more than 28%, that is, 100×(oLVM/pLVM) \>128%.
Interventions
- DRUG Nebivolol
- DRUG Metoprolol succinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-03 |
| Phase | Phase 4 |
Why NCT01605370 stopped before completion
NCT01605370 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Nebivolol is the first listed.
NCT01605370 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01605370 about?
NCT01605370 is a clinical study titled "Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?". The purpose of this study is to evaluate if a drug called nebivolol can reverse inappropriate left ventricular mass (LVM) when compared to the standard of care drug metoprolol.
What is the current status of trial NCT01605370?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2012-06. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01605370?
The interventions under investigation include: Nebivolol (DRUG), Metoprolol succinate (DRUG).
Who is sponsoring clinical trial NCT01605370?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01605370's enrollment target sits among peer trials
1 2000th of 2000 the lowest of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia